Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis

FEN YANG1,2*, XIAO YAN TANG3*, HAO LIU4 and ZHI WEN JIANG4

1Department of Tumor Radiotherapy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui; 2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu; 3Department of Clinical Laboratory, Nanjing Chest Hospital, Nanjing, Jiangsu; 4Department of Pharmacy, Bengbu Medical College, Bengbu, Anhui, P.R. China

Received November 5, 2015; Accepted December 17, 2015

DOI: 10.3892/or.2016.4580

Abstract. Accumulation of unfolded proteins in the endoplasmic reticulum (ER) induces ER stress which is observed in many human diseases, including breast cancer. Cellular adaptation to ER stress is mediated by the unfolded protein response (UPR), which aims at restoring ER homeostasis. Higher levels of GRP78 expression indicates constitutive activation of the UPR in breast cancer leading to breast cancer cells that are relatively resistant to ER stress-induced apoptosis. Tunicamycin (TM), an ER stress inducer, constitutively activates the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK), and (MEK)/ERK pathway which plays a role in upregulation of GRP78 by ER stress in that inhibition of MEK by U0126 reduces the levels of GRP78 and blocks its upregulation by TM. Inhibition of the MEK/ERK pathway by U0126 sensitizes breast cancer cells to TM-induced apoptosis. Inhibition of GRP78 by siRNA knockdown enhances TM- and U0126-induced apoptosis in breast cancer cells. This sensitization of breast cancer cells to TM-induced apoptosis by inhibition of MEK/ERK and GRP78 is caspase-dependent, at least in part, by activation of caspase-4. These results seem to indicate that GRP78 has potential as a chemotherapeutical target and have important implications for new treatment strategies in breast cancer by combination with agents that induce ER stress with inhibitors of the MEK/ERK pathway.

Introduction

Endoplasmic reticulum (ER) is an essential cellular compartment where new secretory proteins are folded and assembled to their maturation. When suffering various conditions such as nutrient deprivation, hypoxia, alterations in glycosylation status and disturbances of calcium flux, the steady state of the ER environment is disturbed and misfolded or unfolded proteins are accumulated and aggregated in ER lumen, failure of ER coping with the excessive proteins load leads to ER stress (1). To reduce damage from ER stress, cells trigger unfolded protein response (UPR), which signals transient attenuation of protein translation, degradation of unfolded and misfolded proteins and the induction of molecular chaperones (2). The upregulation of molecular chaperones in response to expression of dominant negative ubiquitin may contribute to degradation of abnormal proteins (3).

Three known transmembrane sensors of ER stress are double-stranded RNA-activated protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) (4). Under normal conditions, the luminal domains of these sensors are occupied by the ER chaperon glucose-regulated protein 78 (GRP78) (5). Upon ER stress, unfolded or misfolded proteins compete with these sensors for binding GRP78 segregating GRP78 from those of luminal domains. As a result, these sensors are activated by inducing phosphorylation and homodimerization of IRE1 and PERK, and relocation of ATF6 to the Golgi (6,7).

GRP78, is also known as immunoglobulin heavy chain binding protein (BIP), is a central regulator of ER function, an ER molecular chaperon, facilitating new protein folding and assembling, targeting misfolded proteins for degradation, binding ER Ca2+ and controlling the activation of transmembrane ER stress sensors (8,9). Perhaps due to nutrient deprivation and hypoxia, increasing evidence shows that the UPR is indispensable in various solid tumors, investigators have reported elevated expression of UPR targets, such as GRP78 and GRP94 (10,11). The expression of these genes and other components of UPR are also correlated with increased malignancy. It seems that some cancer cells may...
have adapted to ER stress by activation of UPR without resulting in apoptosis (12).

The UPR is a cytoprotective response to ER stress, but excessive or prolonged UPR results in apoptotic cell death. Many caspase family members participate in the process of ER stress-induced apoptosis, such as caspase-2, -3, -4, -7, -8, and -9 and -12 (13-17). Among them, caspase-12 is thought to be a key mediator in rodents. However, caspase-4 has been shown to play an important role in ER stress-induced apoptosis of human neuroblastoma and HeLa cells. Mutual action between caspase-4 and GRP78 suggests that caspase-4 lies in ER lumen (18,19), this provides structural basis for regulation of ER stress-induced apoptosis by caspase-4.

Previous studies have shown that survival signaling pathways, such as the phosphatidylinositol 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) and (MEK)/ERK pathways, may also play roles in counteracting the apoptosis-inducing potential of ER stress. Particularly, constitutive activation of the MEK/ERK pathway is reported as a common cause for resistance of melanoma cells to apoptosis mediated by the death receptor and mitochondrial apoptotic pathways (20-23).

In the present study, we found that UPR was constitutively activated in the breast cancer cells compared to normal breast epithelial cells in which GRP78 expression of cancer cells was obviously higher than epithelial cells. Moreover, we found that tunicamycin (TM), an ER stress inducer, not only strongly activated UPR, but also the MEK/ERK pathway, and inhibition of the pathway sensitized breast cancer cells to TM-induced apoptotic cell death due to downregulation of GRP78 expression. This sensitization of breast cancer cells to TM-induced apoptosis by inhibition of MEK/ERK and GRP78 was caspase-dependent, at least in part, by activation of caspase-4. These results indicated that GRP78 is a possible chemotherapeutical target and have important implications for new treatment strategies in breast cancer by combination of agents that induce ER stress with inhibitors of the MEK/ERK pathway.

Materials and methods

Cell lines. Human breast cancer cell lines MCF-7, MDA-MB-231 and SK-BR-3 were cultured in Department of Biochemistry and Molecular Biology, Nanjing Medical University. Human mammary epithelial cell line MCF-10A and human pignmented case.

Clinical specimens. Clinical specimens were collected from the patients registered at the First Affiliated Hospital of Bengbu Medical College (Bengbu, China) between 2005 and 2008 with the patients consent and Ethics Committee approval. To monitor GRP78 protein immunostaining with clinicopathological stages, patient medical records were retrospectively reviewed at the time when the study sample was obtained. All samples were randomly selected and arranged as three groups: breast cancers, adjacent non-cancerous tissue and breast fibroadenoma.

Antibodies, recombinant proteins and other reagents. The Vectastain ABC kit and the DAB kit were from Wuhan Boster Biotechnology Co. Tunicamycin (TM) was purchased from Sigma Chemical Co. (Castle Hill, Australia), and dissolved in dimethyl sulfoxide (DMSO) and made to stock solutions of 1 mmol/l. The rabbit polyclonal antibody against GRP78, ERK1 and ERK2 were purchased from Santa Cruz Biotechnology Co. The mouse monoclonal antibody against P-ERK1/2 and β-actin were purchased from Sigma Chemical Co. Propidium iodide (PI) was purchased from Sigma Chemical Co. Reverse transcription-qPCR assay kit was from Takara Co. TRIzol was from Invitrogen Co. The siGENOME SMART pool reagents, the siGENOME SMART pool GRP78 (M-008198-01) and control non-targeting siRNA pool (D-001206-13-20) were obtained from Dharmacon. Opti-MEM medium and Lipofectamine 2000 reagent were purchased from Invitrogen Co.

Immunohistochemical staining. Five micrometer-thick sections were cut from the formalin-fixed, paraffin-embedded block of each case. Sections were deparaffinized in xylene and rehydrated through graded decreasing concentrations of alcohol. Antigen was repaired in 0.01 mol/l of citrate buffer (pH 6.0) by heating in a microwave oven for 5 min and repeating three times. Rabbit anti-human GRP78 antibody was added at a dilution of 1:100 in phosphate-buffered saline (PBS) for 1 h at 37˚C. The Vectastain ABC kit was used to bind the antibodies according to the manufacturer's instructions and the binding sites were visualized using the DAB kit. The sections were counterstained with Harris hematoxylin. Negative controls were performed by omission of the primary antibody replaced by PBS in each experiment and each heavy pigmented case.

Each section was observed in 10 HP visual fields (VFs), and 200 cells/VF were counted. Score of positive cells <10% was regarded as 0, 10-50% as 1, 51-75% as 2, and ≥75% as 3. No staining was 0, weakly positive staining was 1, moderately positive staining was 2 and strongly positive staining was 3. An immunoreactive score (IRS) was derived by multiplying the score of percentage of positive cells with the score of staining intensity. IRS=0 was regarded as negative; IRS=4 was weakly positive; and IRS ≥4 was strongly positive.

PI uptake assay and apoptosis. Cells were seeded at 1x10⁵/well into 24-well plates and allowed to reach exponential growth for 16-24 h before treatment. PI staining procedure followed the manufacturer's protocol, PI buffer was mixed with 100 ml dH₂O, 0.005 g PI, 0.1 g trisodium citrate, 100 µl Triton X-100, covering with foil and keeping at 4˚C. Quantitation of apoptotic cells were represented by measurement of sub-G1 DNA content using PI staining in FCM.

Protein extraction and western blot analysis. Whole cell extracts were obtained by lysing cells in a Triton X-100-based lysis buffer (10 mmol/l Tris- HCl pH 7.4, 140 mmol/l NaCl, 0.5 mmol/l CaCl₂, 10.5 mmol/l MgCl₂, 3 mmol/l NaN₃, 2 mmol/l EDTA, 1 mmol/l PMSF, 0.5 mmol/l DTT, 200 mg/ml leupeptin, 100 µg/ml aprotinin, 100 µg/ml trypsin inhibitor, 100 µg/ml soybean trypsin inhibitor, 1 mmol/l NaN₃).
Reverse transcription and quantitative PCR (RT-qPCR). Total RNA was extracted according to the protocol and RNA concentrations were determined spectrophotometrically at 260 nm. Total RNA (1 µg) was reverse transcribed to cDNA in a total volume of 20 µl system using a RT reaction kit (Takara). Quantitative PCR was performed using an Mx3000P Real-Time PCR system (Applied Biosystems) according to the manufacturer's instructions and SYBR Premix Ex Taq (Takara) as a DNA-specific fluorescent dye. PCR was carried out for 40 cycles of 95°C for 10 sec and 60°C for 1 min. All the reactions were repeated three times. Gene expression levels were calculated relative to GAPDH as a 2-ΔΔCt value using Stratagene Mx3000P software. Ratio of the treatment group 2-ΔΔCt value and the negative group represents relative expression levels. The primers used for amplification were as follows: GRP78, 5'-GGGAAGGTGAAGGTCGGAGTC-3' and 5'-AGCAGAGGACCTTCACCATGAGGTTTGCTGATAATTG-3'; GAPDH, 5'-GGGAGGTGAGGTGCAGGTCGG-3' and 5'-AGCAGAGGGGCAGAGATGAT-3'. Primers and probes for GRP78 and GAPDH were from Sangon Co., Shanghai, China.

Small RNA interference (RNAi) transfection. Breast cancer cells MCF-7 and MDA-MB-231 were seeded at 5x10⁴ cells/well in 24-well plates and allowed to reach ~50% confluence on the day of transfection. Cells were transfected with 50-100 nmol/l siRNA in Opti-MEM medium with 10% FCS using Lipofectamine 2000 reagent according to the manufacturer's transfection protocol. Twenty-four hours after transfection, the cells were switched into medium containing 10% FCS and treated as designed before quantitation of apoptotic cells by measurement of sub-G1 DNA content using the PI method in FCM. Efficiency of siRNA transfection was monitored if ER stress induced activation of the MEK/ERK pathway is reported as a commonly accepted reason for resistance of cancer cells to apoptosis. Therefore, we treated MCF-7, MDA-MB-231, MCF-10A and WI-38 cells with TM, which efficiently killed MCF-10A and WI-38 cells with TM, respectively, before use. Extraction for phosphorylated proteins needs adding to 50 mmol/l NaF and 1 mmol/l Na₂VO₃. The protein content of cell extracts was determined by the BCA assay. A total load of 30-40 µg proteins was electrophoresed on 10% SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked, incubated with primary antibody at the appropriate concentration (1:500-1,000), and subsequently incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat antimouse IgG (1:5,000-10,000 dilution). Labeled bands were detected by Renaissance Western Blot Chemiluminescence Reagent (Pierce Co.) and exposed on Hyper MP autoradiography film (Amersham). The densities of the bands were quantitated by Gel Imaging System as proteins relatively expression levels.

Caspase-4 activity assay. Caspase-4 can catalyze substrate acetyl-Leu-Val-Asp p-nitroanilide (Ac-LEVD-pNA) to flavous p-nitroaniline (p-NA) with strong absorbance at the wavelength of 405 nm, thus, absorbance was measured to determine caspase-4 activity. Total proteins were extracted as previously described in western blot analysis and quantitated by Bradford method. Measurement of caspase-4 activity was carried out at the wavelength of 405 nm, according to the manufacturer's protocol.

### Table I. Expression of GRP78 in tissue by immunohistochemistry.

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Cases</th>
<th>0 (%)</th>
<th>1-4 (%)</th>
<th>≥4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast fibroadenoma</td>
<td>20</td>
<td>16(80)</td>
<td>4(20)</td>
<td>0</td>
</tr>
<tr>
<td>Cancer adjacent tissue</td>
<td>50</td>
<td>10(20)</td>
<td>35(70)</td>
<td>5(10)</td>
</tr>
<tr>
<td>Breast cancer tissue</td>
<td>50</td>
<td>1(2)</td>
<td>7(14)</td>
<td>42(84)</td>
</tr>
</tbody>
</table>

GRP78 expression was detected in 20 cases of breast fibroadenoma, 50 cases of breast cancer and 50 cases of cancer adjacent tissue. IRS 0 was regarded as negative; IRS 1-4 was weakly positive; and IRS ≥4 was strongly positive. IRS, immunoreactive score.

Statistical analysis. The statistical software SPSS, version 16.0, and the Student’s t-test were used for statistical analysis. A P-value of <0.05 was considered to indicate a statistical significance.

Results

**GRP78 expression is increased in breast cancer.** In cell lines, GRP78 expression of breast cancer was significantly higher than that of normal epidermic cells both in protein and mRNA levels (Fig. 1A and B). GRP78 expression in paraffin blocks of breast cancer tissues using immunohistochemical staining is shown in Fig. 1C, the tissues were from 50 cases of breast cancer, 50 cases of adjacent non-cancerous tissue and 20 cases of breast fibroadenoma. GRP78 was expressed at significantly higher levels in breast cancer tissues in comparison with that in adjacent non-cancerous tissue and breast fibroadenoma (P<0.01, Dunnette t-test), GRP78 was strongly positive in breast cancer (84%), weakly positive in adjacent non-cancerous tissue (70%), and markedly negative in breast fibroadenoma (80%) (Table I). These results indicated that UPR was constitutively activated in breast cancer.

**Breast cancer cells are relatively resistant to ER stress-induced apoptosis.** We treated MCF-7, MDA-MB-231 cells with TM, an ER stress inducer. TM markedly upregulated GRP78 expression and in 24 h the upregulation peaked (Fig. 2A), indicative of further activation of the UPR. At the same time, we treated MCF-7, MDA-MB-231, MCF-10A and WI-38 cells with TM, respectively, at a range of concentrations for 48 h to study the apoptosis induction potential of ER stress. However, the two breast cancer cell lines were induced from minimal to moderate levels of apoptosis (<30% apoptotic cells), even when used at relatively high concentration (TM at 12 µmol/l), which efficiently killed MCF-10A and WI-38 by induction of apoptosis (Fig. 2B).

**Inhibition of MEK/ERK sensitizes breast cancer cells to ER stress-induced apoptosis.** Constitutive activation of the MEK/ERK pathway is reported as a commonly acceptable reason for resistance of cancer cells to apoptosis. Therefore, we monitored if ER stress induced activation of the MEK/ERK pathway is reported as a commonly acceptable reason for resistance of cancer cells to apoptosis.
pathway by examining phosphorylation (activation) of ERK1/2 in whole cell lysates from MCF-7 and MDA-MB-231 cells with exposure to TM. As shown in Fig. 3A, ERK1/2 was weakly activated in control cell lines, but the levels of activation were constitutively increased by treatment with TM, indicating that ER stress induced further ERK1/2 activation in breast cancer cells. We next measured the effect of MEK inhibition on TM-induced apoptosis in breast cancer cells by treating MCF-7 and MDA-MB-231 cells with the MEK inhibitor U0126 1 h before TM treatment for another 24 h. As shown in Fig. 3B and C, not only U0126 inhibited activation of ERK1/2 in the presence or absence of TM, but it significantly sensitized the cells to TM-induced apoptosis (P<0.01, Student's t-test). However, the MEK inhibitor alone did not cause appreciable apoptotic cell death in the cell lines.

U0126 downregulates GRP78 expression in both protein and mRNA levels. GRP78 is believed to play an essential role in protection of cells from ER stress-induced apoptosis (24). Therefore, we deduced that sensitization of breast cancer cells to ER stress-induced apoptosis by inhibition of MEK/ERK probably related to regulation of GRP78. As shown in Fig. 4A

Figure 1. GRP78 was strongly positive in breast cancer. (A) GRP78 protein expression was strongly positive in breast cancer cell lines MCF-7, MDA-MB-231 and SK-BR-3 compared to normal cell lines MCF-10A and WI-38. (B) GRP78 mRNA expression in breast cancer cell lines was markedly higher than breast normal cell lines. *P<0.01 for breast cancer cell lines MCF-7, MDA-MB-231 and SK-BR-3 compared to normal cell lines MCF-10A, respectively. (C) GRP78 expression was strongly positive in breast cancer tissue, weakly positive in adjacent non-cancerous tissue and negative in breast fibroadenoma. Images were captured at a magnification of x100 and x400. Scale bars, 100 µm in images at a magnification of x100, and 25 µm in images at a magnification of x400.
exposure to U0126, a special MEK inhibitor, resulted in reduction in the levels of GRP78 expression and attenuated its induction by TM in both MCF-7 and MDA-MB-231 cells. To examine if inhibition of MEK/ERK blocked transcription of GRP78, we monitored mRNA levels of GRP78 by RT-qPCR in MCF-7 and MDA-MB-231 cells treated with U0126 1 h before TM treatment. As shown in Fig. 4B, GRP78 mRNA levels in cells treated with TM in the presence of U0126 were markedly lower than those in cells treated with TM alone (P<0.01, Student's t-test).

**GRP78 knockdown by siRNA sensitizes breast cancer cells to ER stress-induced apoptosis.** To further study if sensitization of breast cancer cells to ER stress-induced apoptosis was due...
to reduced GRP78 expression, we used siRNA knock-down of GRP78, then observed ER stress-induced apoptosis by TM in MCF-7 and MDA-MB-231 cells. As shown in Fig. 5A exposure to GRP78 siRNA resulted in blockage of GRP78 expression in both MCF-7 and MDA-MB-231 cells, while control siRNA had no effect on the levels of GRP78 expression, compared to the negative group. As shown in Fig. 5B, inhibition of GRP78 by siRNA resulted in substantial increases in sensitivity of breast cancer cells to apoptosis induced by TM in the absence of U0126 (P<0.01, Student’s t-test). MCF-7 and MDA-MB-231 cells were treated with U0126 1 h before TM treatment, along with GRP78 knockdown by siRNA, which resulted in more significant increases in sensitivity of cells to apoptosis (P<0.01, Student’s t-test). However, inhibition of GRP78 by siRNA only failed to induce significant apoptosis in both MCF-7 and MDA-MB-231 cells.

Caspase-4 activity was monitored to examine whether sensitization of breast cancer cells to TM-induced apoptosis by inhibition of MEK/ERK is caspase-dependent. As shown in Fig. 5C, tunicamycin (TM) or U0126 alone did not constitutively activate caspase-4, whereas, TM along with U0126 markedly activated it in that caspase-4 activity was increased by 2-fold (P<0.05, Student’s t-test). Furthermore, knockdown of GRP78 by siRNA and TM caused an increase of 2-fold caspase-4 activity (P<0.05, Student’s t-test). Altogether GRP78 siRNA with TM in the presence of U0126, caspase-4 was 4-fold increased in both MCF-7 and MDA-MB-231 cells (P<0.01, Student’s t-test).

Discussion

Resistance to chemotherapy is a major obstacle to improving therapeutic effects of breast cancer. The study of resistance mechanisms is becoming a new strategy of overcoming various cancers. The above results suggest that there are two apoptotic resistance mechanisms in breast cancer which are constitutively activation of MEK/ERK pathway and stress induction of the UPR. GRP78 was found to be expressed at relatively high levels in cultured breast cancer cells and tissue, but were at low levels in cultured breast normal epithelial cells and normal tissue, which suggest that the UPR may have tumor-specific selectivity. The strongly positive GRP78 expression suggests that the UPR is acutely activated in breast cancer and targeted therapy against breast cancer via surface GRP78 may antagonize the cyto-protective UPR.

TM, an ER stress inducer, markedly upregulated GRP78 expression and in 24 h the upregulation peaked. Furthermore, cultured breast cancer cells did not undergo significant
activated ER stress in cancer cells and further activated UPR. Obviously, TM aggravated ER stress when submitted to extreme degrees of ER stress induced by TM, but the same treatment induced significant apoptosis in normal epithelial cells. It is indicated that the cyto-protective UPR is the base of tumor resistance and GRP78 plays a central role in the process.

The MAPK pathway is known to be activated in a broad spectrum of human tumors, including human colorectal (25) and gastric cancer (26) and melanoma (27). We observed that activation of the MEK/ERK pathway was relatively weak in breast cancer cells, yet TM induced constitutive activation of the pathway as evidenced by increased phosphorylation (activation) form of ERK1/2 (P-ERK1/2). The MEK inhibitor was found to downregulate GRP78 expression and block activation of the UPR induced by TM. This indicates that activation of the MEK/ERK pathway plays an important role in upregulation of GRP78 by ER stress. In light of these results, we consider that the MEK inhibitor functions upstream of the activation of UPR and inhibiting the activation of survival pathway MEK/ERK blocks the cyto-protective role of the UPR. It was confirmed by ER stress-induced apoptosis, which is readily triggered when the MEK/ERK pathway is inhibited by the MEK inhibitor U0126. We also found that the MEK inhibitor alone did not cause appreciable apoptotic cell death in breast cancer cells. Therefore the MEK/ERK pathway inhibition would be responsible for the increasing sensitivity of ER stress-induced apoptosis. Furthermore, the chaperon GRP78 seems to be a target of the MEK/ERK pathway responsible for the inhibition of ER stress-induced apoptosis. We consider that inhibiting GRP78 expression may enhance ER stress-induced apoptosis.

GRP78 expression is primarily regulated at the transcriptional level, mediated by multiple copies of the ER stress response element within the GRP78 promoter region (28). We showed by RT-qPCR that GRP78 mRNA levels were decreased by inhibition of MEK/ERK in the presence or absence of TM, indicating that the MEK/ERK pathway may participate in regulation of GRP78 transcription. GRP78 is induced in a wide variety of cancer cells and cancer biopsy tissue. The identification of the transcription factors interacting with the ER stress response element leads to the discovery of multiple pathways whereby mammalian cells can sense ER stress and trigger the transcription of GRP78 (29). We utilized GRP78 knockdown by siRNA resulting in significant increases in cell death in breast cancer cells. Therefore the MEK/ERK pathway inhibition would be responsible for the increasing sensitivity of ER stress-induced apoptosis. Furthermore, the chaperon GRP78 seems to be a target of the MEK/ERK pathway responsible for the inhibition of ER stress-induced apoptosis. We consider that inhibiting GRP78 expression may enhance ER stress-induced apoptosis.

We also found that sensitization of breast cancer cells to TM-induced apoptosis by inhibition of MEK/ERK was caspase-4 dependent, in that when TM induced ER stress, caspase-4 activity was lower, yet MEK/ERK inhibition and GRP78 knockdown increased levels of caspase-4 activity. Caspase-4 is an apical caspase in induction of apoptosis by TM in the presence of U0126, activation of caspase-4 necessarily switched on caspase cascade responses to apoptosis. Moreover, inhibition of GRP78 by siRNA
enhanced activation of caspase-4 induced by TM. These results indicate that GRP78 may participate in controlling the activation of caspase-4 in breast cancer cells.

In summary, GRP78 knockdown resulted in significant increases in sensitivity of cells to apoptosis by TM. Inhibition of MEK/ERK may sensitize breast cancer cells to TM-induced apoptosis. The results indicate that it may be an effective strategy against breast cancer to combine agents that induce ER stress with those inhibiting the MEK/ERK pathway. However, normal cells WI-38 and MCF-10A seem to have tumor-specific selectivity and thus being useful in treatment of breast cancer, this role is due, at least partly, to activation of caspase-4. GRP78 may be a potential target against breast cancer tissues, but is hardly detectable in WI-38, MCF-10A and breast fibroadenoma. This suggests that targeting GRP78 may have high levels in cultured breast cancer cells and breast cancer tissues, but is hardly detectable in WI-38, MCF-10A and breast fibroadenoma. This suggests that targeting GRP78 may have tumor-specific selectivity and thus being useful in treatment of breast cancer, this role is due, at least partly, to activation of caspase-4. GRP78 may be a potential target against breast cancer, and small molecular inhibitor targeting GRP78 in combination with inhibitors targeting the MEK/ERK pathway is required before in vivo investigations being carried out. Of interest, GRP78 is found to be expressed at relatively high levels in cultured breast cancer cells and breast cancer tissues, but is hardly detectable in WI-38, MCF-10A and breast fibroadenoma. This suggests that targeting GRP78 may have tumor-specific selectivity and thus being useful in treatment of breast cancer, this role is due, at least partly, to activation of caspase-4. GRP78 may be a potential target against breast cancer, and small molecular inhibitor targeting GRP78 in combination with those inducing ER stress, is a promising chemotherapeutical plan against breast cancer.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (31401094).

References


